Inotiv (NOTV) Expected to Announce Quarterly Earnings on Wednesday

Inotiv (NASDAQ:NOTV) is expected to post its Q3 2026 resultson Wednesday, August 5th. Analysts expect Inotiv to announce earnings of ($0.47) per share and revenue of $136.6840 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Inotiv (NASDAQ:NOTV) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.30). Inotiv had a negative net margin of 17.14% and a negative return on equity of 56.77%. The firm had revenue of $117.65 million for the quarter, compared to the consensus estimate of $124.74 million.

Inotiv Stock Performance

NOTV opened at $0.01 on Wednesday. Inotiv has a one year low of $0.08 and a one year high of $2.95. The stock’s fifty day moving average is $0.08 and its 200-day moving average is $0.26. The company has a market capitalization of $387,256.80, a PE ratio of -0.00 and a beta of 3.77.

Hedge Funds Weigh In On Inotiv

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its position in shares of Inotiv by 5,660.0% during the third quarter. Bank of America Corp DE now owns 21,888 shares of the company’s stock worth $32,000 after purchasing an additional 21,508 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Inotiv in the 2nd quarter valued at $44,000. American Century Companies Inc. increased its stake in Inotiv by 16.4% in the 2nd quarter. American Century Companies Inc. now owns 41,933 shares of the company’s stock worth $76,000 after purchasing an additional 5,894 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Inotiv by 11,118.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 48,015 shares of the company’s stock worth $70,000 after purchasing an additional 47,587 shares in the last quarter. Finally, Squarepoint Ops LLC raised its holdings in Inotiv by 304.2% during the 4th quarter. Squarepoint Ops LLC now owns 59,202 shares of the company’s stock worth $33,000 after buying an additional 44,554 shares during the period. 18.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inotiv in a research note on Friday, April 10th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $1.50.

About Inotiv

Inotiv, Inc, formerly known as Bioanalytical Systems, Inc (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.

The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support.